Beyond the antigen receptor: Editing the genome of T-cells for cancer adoptive cellular therapies

Frontiers in Immunology

Volumn 4, Issue AUG, 2013, Pages

  Lloy, Angharad ^a   Vickery, Owen N ^a   Laugel, Bruno ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Cancer; Cell therapies; Genome editing; Immune checkpoints; T cells

Indexed keywords

ADENOSINE A2 RECEPTOR; DNA BINDING PROTEIN; ENDONUCLEASE; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROGRAMMED DEATH 1 RECEPTOR; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E2; PROTEIN TYROSINE PHOSPHATASE SHP 1; SHORT HAIRPIN RNA; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR AP 1; ZINC FINGER PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; AUTOIMMUNITY; CANCER THERAPY; CELLULAR IMMUNITY; DNA SEQUENCE; GENE EXPRESSION; GENETIC ENGINEERING; GENOME EDITING; GENOMICS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; PROTEIN EXPRESSION; RNA INTERFERENCE; TREATMENT OUTCOME;

EID: 84883732428     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00221     Document Type: Article

References (69)

1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in. Science (2011) 331(6024):1565-70. doi:10.1126/science.1203486
2. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature (2011) 480:480-9. doi:10.1038/nature10673
3. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 239:27-44. doi:10.1111/j.1600-065X.2010.00979.x
4. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 365:725-33. doi:10.1056/NEJMoa1103849
5. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 29:917-24. doi:10.1200/JCO.2010.32.2537
6. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 17:4550-7. doi:10.1158/1078-0432.CCR-11-0116
7. Blank CU, Hooijkaas AI, Haanen JB, Schumacher TN. Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol Immunother (2011) 60:1359-71. doi:10.1007/s00262-011-1079-2
8. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 12:237-51. doi:10.1038/nrc3237
9. Noh KH, Kang TH, Kim JH, Pai SI, Lin KY, Hung CF, et al. Activation of Akt as a mechanism for tumor immune evasion. Mol Ther (2009) 17:439-47. doi:10.1038/mt.2008.255
10. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 70:5213-9. doi:10.1158/0008-5472.CAN-10-0118
11. Martinez Forero I, Okada H, Topalian SL, Gajewski TF, Korman AJ, Melero I. Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011. J Transl Med (2012) 10:108. doi:10.1186/1479-5876-10-108
12. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12:252-64. doi:10.1038/nrc3239
13. An DS, Qin FX, Auyeung VC, Mao SH, Kung SK, Baltimore D, et al. Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors. Mol Ther (2006) 14:494-504. doi:10.1016/j.ymthe.2006.05.015
14. Yi R, Doehle BP, Qin Y, Macara IG, Cullen BR. Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. RNA (2005) 11:220-6. doi:10.1261/rna.7233305
15. Castanotto D, Sakurai K, Lingeman R, Li H, Shively L, Aagaard L, et al. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res (2007) 35:5154-64. doi:10.1093/nar/gkm543
16. Couto LB, High KA. Viral vector-mediated RNA interference. Curr Opin Pharmacol (2010) 10:534-42. doi:10.1016/j.coph.2010.06.007
17. Sanjana NE, Cong L, Zhou Y, Cunniff MM, Feng G, Zhang F. A transcription activator-like effector toolbox for genome engineering. Nat Protoc (2012) 7:171-92. doi:10.1038/nprot.2011.431
18. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet (2010) 11:636-46. doi:10.1038/nrg2842
19. Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol (2013) 31:227-9. doi:10.1038/nbt.2501
20. Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C, et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res (2011) 39:e82. doi:10.1093/nar/gkr218
21. Wolfe SA, Nekludova L, Pabo CO. DNA recognition by Cys2His2 zinc finger proteins. Annu Rev Biophys Biomol Struct (2000) 29:183-212. doi:10.1146/annurev.biophys.29.1.183
22. Hockemeyer D, Soldner F, Beard C, Gao Q, Mitalipova M, DeKelver RC, et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol (2009) 27:851-7. doi:10.1038/nbt.1562
23. Kim Y, Kweon J, Kim A, Chon JK, Yoo JY, Kim HJH, et al. A library of TAL effector nucleases spanning the human genome. Nat Biotechnol (2013) 31:251-8. doi:10.1038/nbt.2517
24. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature (2005) 435:646-51. doi:10.1038/nature03556
25. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol (2011) 29:143-8. doi:10.1038/nbt.1755
26. Christian M, Cermak T, Doyle EL, Schmidt C, Zhang F, Hummel A, et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics (2010) 186:757-61. doi:10.1534/genetics.110.120717
27. Brouns SJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJ, Snijders AP, et al. Small CRISPR RNAs guide antiviral defense in prokaryotes. Science (2008) 321:960-4. doi:10.1126/science.1159689
28. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (2012) 337:816-21. doi:10.1126/science.1225829
29. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 339:819-23. doi:10.1126/science.1231143
30. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science (2013) 339:823-6. doi:10.1126/science.1232033
31. Habib N, Hsu PD, Wu X, Jiang W, Luciano A, Cong L, et al. Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 339:819-23. doi:10.1126/science.1231143
32. Ding Q, Regan SN, Xia Y, Oostrom LA, Cowan CA, Musunuru K. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell (2013) 12:393-4. doi:10.1016/j.stem.2013.03.006
33. van der Oost J. Molecular biology. New tool for genome surgery. Science (2013) 339:768-70. doi:10.1126/science.1234726
34. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol (2007) 25:1298-306. doi:10.1038/nbt1353
35. Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med (2012) 18:807-15. doi:10.1038/nm.2700
36. Holkers M, Maggio I, Liu J, Janssen JM, Miselli F, Mussolino C, et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res (2012) 41(5):e63. doi:10.1093/nar/gks1446
37. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 26:808-16. doi:10.1038/nbt1410
38. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science (2011) 332:600-3. doi:10.1126/science.1202947
39. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 192:1027-34. doi:10.1084/jem.192.7.1027
40. + T cells. EMBO Mol Med (2011) 3:581-92. doi:10.1002/emmm.201100165
41. Wherry EJ. T cell exhaustion. Nat Immunol (2011) 12:492-9. doi:10.1038/ni.2035
42. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 24:207-12. doi:10.1016/j.coi.2011.12.009
43. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology (2012) 1:1223-5. doi:10.4161/onci.21335
44. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2012) 72:917-27. doi:10.1158/0008-5472.CAN-11-1620
45. Fougeray S, Brignone C, Triebel F. A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: preclinical evaluation of IMP321. Vaccine (2006) 24:5426-33. doi:10.1016/j.vaccine.2006.03.050
46. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366:2443-54. doi:10.1056/NEJMoa1200690
47. Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res (2010) 70:2245-55. doi:10.1158/0008-5472.CAN-09-3109
48. Häusler SF, Montalbán del Barrio I, Strohschein J, Anoop Chandran P, Engel JB, Hönig A, et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother (2011) 60:1405-18. doi:10.1007/s00262-011-1040-4
49. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature (2001) 414:916-20. doi:10.1038/414916a
50. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MKK, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA (2006) 103:13132-7. doi:10.1073/pnas.0605251103
51. Sitkovsky M, Ohta A. Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer. J Mol Med (Berl) (2013) 91:147-55. doi:10.1007/s00109-013-1001-9
52. Ohta A, Kjaergaard J, Sharma S, Mohsin M, Goel N, Madasu M, et al. In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression. Br J Pharmacol (2009) 156:297-306. doi:10.1111/j.1476-5381.2008.00019.x
53. +CD45RO+ T cells. Blood (2010) 116:2253-65. doi:10.1182/blood-2010-01-266650
54. Mosenden R, Tasken K. Cyclic AMP-mediated immune regulation - overview of mechanisms of action in T cells. Cell Signal (2011) 23:1009-16. doi:10.1016/j.cellsig.2010.11.018
55. Stromnes IM, Fowler C, Casamina CC, Georgopolos CM, McAfee MS, Schmitt TM, et al. Abrogation of SRC homology region 2 domain-containing phosphatase 1 in tumor-specific T cells improves efficacy of adoptive immunotherapy by enhancing the effector function and accumulation of short-lived effector T cells in vivo. J Immunol (2012) 189:1812-25. doi:10.4049/jimmunol.1200552
56. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 26:677-704. doi:10.1146/annurev.immunol.26.021607.090331
57. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 25:9543-53. doi:10.1128/MCB.25.21.9543-9553.2005
58. Turnis ME, Korman AJ, Drake CG, Vignali DA. Combinatorial immunotherapy: PD-1 may not be LAG-ing behind any more. Oncoimmunology (2012) 1:1172-4. doi:10.4161/onci.20593
59. Murphy KM, Nelson CA, Sedý JR. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol (2006) 6:671-81. doi:10.1038/nri1917
60. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol (2003) 4:670-9. doi:10.1038/ni944
61. Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, Oltean D, et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. Mian Yi Xue Za Zhi (2007) 178:5595-605.
62. Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B. CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun (2008) 366:117-22. doi:10.1016/j.bbrc.2007.11.103
63. Pallasch CP, Ulbrich S, Brinker R, Hallek M, Uger RA, Wendtner C-M. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk Res (2009) 33:460-4. doi:10.1016/j.leukres.2008.08.021
64. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol (2005) 6:1245-52. doi:10.1038/ni1271
65. Joller N, Hafler JP, Brynedal B, Kassam N, Spoerl S, Levin SD, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. Mian Yi Xue Za Zhi (2011) 186:1338-42. doi:10.4049/jimmunol.1003081
66. Lebbink RJ, de Ruiter T, Adelmeijer J, Brenkman AB, van Helvoort JM, Koch M, et al. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. J Exp Med (2006) 203:1419-25. doi:10.1084/jem.20052554
67. Meyaard L. The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol (2008) 83:799-803. doi:10.1189/jlb.0907609
68. + adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. Mian Yi Xue Za Zhi (2006) 177:246-54.
69. + T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res (2007) 67:5949-56. doi:10.1158/0008-5472.CAN-06-4249